CRISPR Therapeutics stock jumps on early gene editing data

Allison DeAngelis
CRISPR Therapeutics stock jumps on early gene editing data

CRISPR Therapeutics and Vertex Pharmaceuticals released the first data from their early-stage trial testing the safety and effectiveness of a potential cure for the genetic blood disorders sickle cell disease and beta thalassemia.